Imatinib Mesylate Tablet
Product Images NDC 0832-0532

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0832-0532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Structural Formula (Image 3)

Chemical structure of imatinib mesylate showing its molecular arrangement with various rings and functional groups, including a methylsulfonic acid (mesylate) part depicted as .CH3SO3H.*

FDA Label Image

Figure 1 Progression Free Survival (itt Principle) (Image 4)

A survival curve graph showing percentage of patients without progression over 72 months since randomization. The graph compares two groups: the Imatinib Mesylate arm (solid line) and the IFN+Ara-C arm (dashed line). The Imatinib Mesylate group shows higher progression-free survival. A table within the graph provides patient numbers, hazard ratio, confidence interval, and statistical significance (P<0.0001).*

FDA Label Image

Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Image 5)

A Kaplan-Meier survival curve chart showing the percentage of patients without progression to acute promyelocytic leukemia or blast crisis (AP/BC) over 72 months since randomization. The chart compares two groups: one treated with Imatinib Mesylate and the other with IFN+Ara-C, including patient numbers, hazard ratio with confidence interval, and p-value for statistical significance.*

FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Image 6)

A survival probability curve chart comparing imatinib mesylate 400 mg and placebo over time in months. The y-axis represents the probability of being alive and recurrence-free, while the x-axis shows survival time in months. Data points include numbers of patients at risk for each group at various time intervals.*

FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Image 7)

A survival curve chart showing the probability of recurrence-free survival over time in months for two groups receiving imatinib at 12 months and 36 months. The graph includes hazard ratio, confidence interval, p-value, censored observations, sample sizes at risk, and events for each group.*

FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Image 8)

A survival curve graph illustrating the probability of overall survival over a study period in months. The graph compares two groups: one treated with imatinib for 12 months and the other for 36 months, with censored observations marked. Additional data include hazard ratio, confidence intervals, and numbers at risk with event counts over time.*

FDA Label Image

Imatinib Mesylate Tablets 100 mg Bottle Label (Imt 100mg 90s Label)

imatinib mesylate 100 mg tablets label from Upsher-Smith Laboratories, LLC for oral use. The rectangular label shows the product name, strength 100 mg, quantity of 90 tablets, and storage instructions. It includes the NDC 0832-0532-09 and states the product is prescription only, made in China, with handling details and distributor information.*

FDA Label Image

Imatinib Mesylate Tablets 400 mg Bottle Label (Imt 400mg 30s Label)

Label for Imatinib Mesylate Tablets 400 mg by Upsher-Smith Laboratories, LLC. The label indicates a package containing 30 oral tablets. Instructions mention storage conditions and caution to keep out of reach of children. The label includes the NDC number 0832-0533-03 and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.